Enzymatic characteristics of CYP3A5 and CYP3A4:: A comparison of in vitro kinetic and drug-drug interaction patterns

被引:41
|
作者
Emoto, C. [1 ]
Iwasaki, K. [1 ]
机构
[1] Pfizer Japan Inc, Dept Pharmacokinet Dynam Metab, Nagoya Labs, Aichi 4702393, Japan
关键词
CYP3A4; CYP3A5; alpha-naphthoflavone; interaction;
D O I
10.1080/00498250500489968
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
CYP3A4 and CYP3A5 exhibit significant overlap in substrate specificity, but can differ in catalytic activity and regioselectivity. To investigate their characteristics further, the enzymatic reactions of the two CYP3A enzymes were compared using midazolam, nifedipine, testosterone and terfenadine as substrates. Both CYP3A5 and CYP3A4 showed sigmoid and substrate inhibition patterns for testosterone 6 beta-hydroxylation and terfenadine t-butylhydroxylation (TFDOH), respectively. In the other reactions, the kinetic model for CYP3A5 was not similar to that for CYP3A4. An inhibition study demonstrated that the interactions between alpha-naphthoflavone (alpha NF) and CYP3A substrates were different for the two CYP3A enzymes. alpha NF stimulated nifedipine oxidation catalysed by CYP3A5, but did not stimulate that catalysed by CYP3A4. alpha NF at less than 32 mu M inhibited TFDOH catalysed by CYP3A5, but did not inhibit that catalysed by CYP3A4. These results indicate that CYP3A5 has different enzymatic characteristics from CYP3A4 in some CYP3A catalysed reactions.
引用
收藏
页码:219 / 233
页数:15
相关论文
共 50 条
  • [41] Expression and localization of CYP3A4 and CYP3A5 in human lung
    Anttila, S
    Hukkanen, J
    Hakkola, J
    Stjernvall, T
    Beaune, P
    Edwards, RJ
    Boobis, AR
    Pelkonen, O
    Raunio, H
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1997, 16 (03) : 242 - 249
  • [42] Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7
    Williams, JA
    Ring, BJ
    Cantrell, VE
    Jones, DR
    Eckstein, J
    Ruterbories, K
    Hamman, MA
    Hall, SD
    Wrighton, SA
    DRUG METABOLISM AND DISPOSITION, 2002, 30 (08) : 883 - 891
  • [43] CYP3A5 and not CYP3A4 is present in peripheral blood.
    Janardan, SK
    Lown, KS
    SchmiedlinRen, P
    Watkins, PB
    GASTROENTEROLOGY, 1996, 110 (04) : A1222 - A1222
  • [44] Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 Transgenic Mouse Models To Assess the Magnitude of CYP3A4 Mediated Drug-Drug Interactions
    Ly, Justin Q.
    Messick, Kirsten
    Qin, Ann
    Takahashi, Ryan H.
    Choo, Edna F.
    MOLECULAR PHARMACEUTICS, 2017, 14 (05) : 1754 - 1759
  • [45] Predicting the Drug-Drug Interaction Mediated by CYP3A4 Inhibition: Method Development and Performance Evaluation
    Ren, Hong-can
    Sai, Yang
    Chen, Tao
    Zhang, Chun
    Tang, Lily
    Yang, Cheng-guang
    AAPS JOURNAL, 2021, 24 (01):
  • [46] A new drug-drug interaction-tilmicosin reduces the metabolism of enrofloxacin through CYP3A4
    Zhang, Liyun
    Wang, XiaoJing
    Wang, Lei
    Badawy, Sara
    Liu, Zhenli
    Xie, Changqing
    Wang, Xu
    Tao, Yanfei
    RESEARCH IN VETERINARY SCIENCE, 2022, 148 : 33 - 41
  • [48] Pharmacokinetic drug-drug interaction between ethinyl estradiol and gestodene, administered as a transdermal fertility control patch, and two CYP3A4 inhibitors and a CYP3A4 substrate
    Winkler, Julia
    Goldammer, Mark
    Ludwig, Matthias
    Rohde, Beate
    Zurth, Christian
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2015, 40 (04) : 389 - 399
  • [49] Effect of CYP3A5 genotype on the relationship between hepatic CYP3A activity and CYP3A4 and CYP3A5 mRNA expression
    Kolwankar, D
    Ho, H
    Ethell, B
    Vuppalanchi, R
    Marri, SR
    Wrighton, SA
    Jones, DR
    Hall, SD
    DRUG METABOLISM REVIEWS, 2004, 36 : 118 - 118
  • [50] Drug-Drug Interaction Studies to Evaluate the Effect of Inhibition of UGT1A1 and CYP3A4 and Induction of CYP3A4 on the Pharmacokinetics of Tropifexor in Healthy Subjects
    Chen, Jin
    Stringer, Rowan
    Shah, Bharti
    Gu, Jessie
    Zhang, Yiming
    Hackling, Melissa
    Prince, William
    Woessner, Ralph
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (11): : 1253 - 1263